Dataset Information

Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic ¹⁸ F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma Patients.

ABSTRACT: This study aimed to investigate if combining clinical characteristics with pre-therapeutic ¹⁸ F-fluorodeoxyglucose (¹⁸ F-FDG) positron emission tomography (PET) radiomics could predict the presence of molecular alteration(s) in key molecular targets in lung adenocarcinoma. This non-interventional monocentric study included patients with newly diagnosed lung adenocarcinoma referred for baseline PET who had tumour molecular analyses. The data were randomly split into training and test datasets. LASSO regression with 100-fold cross-validation was performed, including sex, age, smoking history, AJCC cancer stage and 31 PET variables. In total, 109 patients were analysed, and it was found that 63 (57.8%) patients had at least one molecular alteration. Using the training da

SUBMITTER: Aide N

PROVIDER: S-EPMC9601118 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic ¹⁸ F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma Patients.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic 18 F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma Patients.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Prediction of the Presence of Targetable Molecular Alteration(s) with Clinico-Metabolic ¹⁸ F-FDG PET Radiomics in Non-Asian Lung Adenocarcinoma Patients.